Back to Press Releases

Revance Announces Julianne Hough as the Celebrity Brand Partner for DAXXIFY® Brand Injectable

Discover the DAXXIFY Difference: The first and only frown line treatment with a peptide formulation.*¹

Nashville, TN – June 23, 2026 – Revance, a global aesthetics, regenerative and consumer skincare company, is proud to announce world renowned dancer, actress and host Julianne Hough as the newest celebrity brand partner for DAXXIFY (daxibotulinumtoxinA-lanm for injection). The partnership serves as part of DAXXIFY’s awareness and consumer education campaign which encourages consumers to try the fast-acting, innovative formula that DAXXIFY offers.

DAXXIFY is the first and only frown line treatment with an innovative peptide formulation, smoothing even the deepest of lines and delivering a radiant look.‡1 The treatment acts fast, with results seen as early as one day and typically within two days, and effects are long-lasting with a gradual softening over time.*†1

“I had been intrigued by DAXXIFY long before formally working with the brand, after realizing I needed a product to better align with my extremely busy schedule,” shared Hough. “I am constantly on the go, and am more often than not on camera dancing, acting and hosting. DAXXIFY fits seamlessly into that lifestyle. More time between visits with my provider means more time doing what I love.”

The campaign will feature Hough educating consumers on the benefits of DAXXIFY and sharing why she personally recommends the treatment and has made the switch herself.  Hough will shoot content to live on her social media channels as well as on DAXXIFY platforms. The social media campaign will be further supported with a media spend to drive more consumer awareness and engagement. 

“We’re thrilled to welcome Julianne as our new brand partner for DAXXIFY, the first innovation in frown line treatments in 20 years,” 3-7 said Adelle Walker, Chief Marketing Officer, Aesthetics at Revance. “This partnership marks an exciting milestone for the brand as we work to expand consumer awareness of DAXXIFY, which is the fastest growing neurotoxin in the U.S.” 2 

_49A9354.jpg

Visit DAXXIFY.com to learn more and find a provider near you. 




IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) injection  

DAXXIFY® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of DAXXIFY®:  
• Problems swallowing, speaking, or breathing due to weakening of associated muscles can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.  
• Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms that include loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.  

Do not receive DAXXIFY® if you are allergic to any of the ingredients in DAXXIFY® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®/BOTOX® Cosmetic), abobotulinumtoxinA (DYSPORT®), incobotulinumtoxinA (XEOMIN®) or prabotulinumtoxinA-xvfs (JEUVEAU®); or have a skin infection at the planned injection site. 

DAXXIFY® dosing units are not the same as, or comparable to, any other botulinum toxin product.  

Tell your healthcare provider about all your medical conditions, including any side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles; drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed.  

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.  

Using DAXXIFY® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received DAXXIFY® in the past.  

Especially tell your healthcare provider if you have received any other botulinum toxin product in the last 4 months or any in the past, and exactly which product you received (such as BOTOX®, BOTOX® Cosmetic, MYOBLOC®, DYSPORT®, XEOMIN®, or JEUVEAU®). DAXXIFY® may cause serious side effects, including allergic reactions (such as itching, rash, redness, swelling, wheezing, trouble breathing, or dizziness or feeling faint), heart problems (such as irregular heartbeat and heart attack), and eye problems (including dry eye, reduced blinking, and corneal problems). Tell your healthcare provider or get medical help right away if you experience a serious side effect. No serious adverse events of distant spread of toxin effect associated with dermatologic use of DAXXIFY® have been reported in clinical studies at the dose of 40 Units for glabellar lines. The most common side effects of DAXXIFY® include headache, eyelid drooping, and loss of ability to move the muscles in your face.  

These are not all the possible side effects of DAXXIFY®. For more information, see the full Prescribing Information including Boxed Warning, and refer to the Medication Guide or talk with your doctor. To report side effects associated with DAXXIFY®, please call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.  

APPROVED USE  
DAXXIFY® is a prescription medicine that is injected into muscles and used in adults to temporarily improve the look of moderate to severe frown lines between the eyebrows. 

DAXI-001723.2 




*In clinical trial diaries, patients reported seeing a measurable improvement within 2 days of treatment.

⁠†74% achieved a ≥ 2-grade improvement at week 4 per both physician's and patient’s assessment. More than 50% had no or minor frown lines until 6 months after treatment per both physician's and patient's assessments.

⁠‡In an open-label study (N=27), 89% of patients agreed their skin looked radiant/bright (exploratory endpoint) and 96% of patients agreed their skin looked smooth in the glabella (exploratory endpoints).  

  1. DAXXIFY® Patient Brochure. Revance Therapeutics, Inc; 2025.
  2. ⁠DOF US Facial Injectables Market Tracker 2025, p10A.
  3. ⁠DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc, 2023.
  4. ⁠Botox® Cosmetic. Prescribing Information. Allergan Inc; 2024.
  5. ⁠Xeomin®. Prescribing Information. Merz Pharmaceuticals GmbH; 2026.
  6. ⁠Dysport®. Prescribing Information. Ipsen Biopharm Ltd; 2023.
  7. ⁠Jeuveau®. Prescribing Information. Evolus, Inc; 2023. 

About Revance  
Revance is a global company developing, producing, and distributing industry-leading, differentiated products across aesthetics, skincare, and therapeutics. Revance drives innovation beyond convention to offer treatment options for individuals across generations. The company’s vision is to redefine excellence in aesthetics, skincare, and therapeutics through science-powered innovation, with an unwavering commitment to its providers, patients, and consumers. Revance’s award-winning products are the result of robust research and development, a cornerstone for the company, driven by renowned scientists. For more information about Revance, please visit us at www.revance.com.  

Media Contact:  
EvolveMKD 
Revance@EvolveMKD.com 


### 

 

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) injection, Teoxane RHA® Collection, and SkinPen®

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines...

DAXXIFY® (daxibotulinumtoxinA-lanm) injection IMPORTANT SAFETY INFORMATION

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION


Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency units of DAXXIFY® are not interchangeable with preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:
Glabellar lines (≥1%): headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Cervical dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

[DAXI-004726]

The long-term efficacy and safety outcomes of RHA® with lidocaine are applicable to RHA® with mepivacaine and mepivacaine has shown no significant impact on gel properties, including rheology and degradation profile.

PLEASE SEE FULL DIRECTIONS FOR USE

RHA® Collection of Fillers, by Teoxane

Indications


The Teoxane RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity®, RHA® 2, RHA® 3 and RHA® 4 with lidocaine and RHA Redensity® Mepi, RHA® 2 Mepi, RHA® 3 Mepi and RHA® Dynamic Volume, with mepivacaine.

RHA Redensity® and RHA Redensity® Mepi are indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older. RHA® 2 and RHA® 2 Mepi are indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) in adults 22 or older. RHA® 3 and RHA® 3 Mepi are indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) and is also indicated for injection into the vermillion body, vermillion border and oral commissure to achieve lip augmentation and lip fullness in adults 22 or older. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) in adults 22 or older. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) and for injection into the subcutaneous to supraperiosteal layers for cheek augmentation and/or correction of age-related midface contour deficiencies in adults 22 or older.

IMPORTANT SAFETY INFORMATION


Contraindications


Do not use in patients who have severe allergies, marked by a history of anaphylaxis or multiple severe allergies, or in patients with a history of allergies to gram-positive bacterial proteins or local anesthetics of the amide type, such as lidocaine and mepivacaine.

Do not use in patients with bleeding disorders.

Warnings


Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures.

Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur.

Product use at specific sites in which an active inflammatory process or infection is present should be deferred until the underlying process has been controlled.

Precautions


These products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy.

Discuss the potential risks of soft-tissue injections with your patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.

The safety and effectiveness for the treatment of anatomic regions other than the labeled indications have not been established in controlled U.S. clinical studies

As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed.

The safety for use in sites in the presence of other implants, during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied.

Use with caution in patients on immunosuppressive therapy.

Patients who are using products that can prolong bleeding (such as thrombolytics, anticoagulants, or inhibitors of platelet aggregation) may experience increased bruising or bleeding at treatment sites.

Patients with a history of herpetic eruptions may experience reactivation of the herpes.

There is a possible risk of inflammation at the implant site if laser treatments or a chemical peel are performed after treatment.

Use as supplied. Modification or use of the product outside the Directions for Use may adversely impact the sterility, safety, homogeneity, or performance of the product.

For single patient use. Do not reuse a syringe between two treatments and/or between two patients. Do not resterilize.

Adverse Events


The most commonly reported side effects were firmness, redness, tenderness, swelling, lumps/bumps, bruising, discoloration, pain and itching. Most of these events were mild or moderate and resolved within 14 days.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.

To report an adverse event with any RHA® product to Revance, please visit Safety.Revance.com or call at 1 (877) 373-8669.

RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.

Available by Prescription only

RHA-00221

The SkinPen system is a microneedling device and accessories intended to be used as a treatment to improve the appearance of wrinkles of the neck for Fitzpatrick skin types II – IV and to improve the appearance of facial acne scars in adults with all Fitzpatrick skin types aged 22 years and older. Rx only. To view SkinPen intended use, important safety information, and clinical trial details (data on file), contact us at regenerativemarketing@revance.com.

SkinPen®

Indications for Use

The SkinPen® Precision Elite, SkinPen® Precision and MicroPen EVO™ systems are microneedling devices and accessories intended to be used as a treatment to improve the appearance of wrinkles of the neck for Fitzpatrick skin types II - IV and to improve the appearance of facial acne scars in adults with all Fitzpatrick skin types aged 22 years and older. Indications and body treatment areas may vary based on your country.

Contraindications

The use of the SkinPen® Precision Elite, SkinPen® Precision and MicroPen EVO™ systems should not be used on patients who have active skin cancer in the treatment area(s), have open wounds, sores, or irritated skin in the treatment area(s), have an allergy to stainless steel or anesthetics, have a hemorrhagic (bleeding) disorder or hemostatic (bleeding) dysfunction, are pregnant or nursing, are currently taking drugs with the ingredient isotretinoin (such as Accutane®). Note: These products are not intended for transdermal (under the skin) delivery of topical products such as cosmetics, drugs, or biologics. For full safety information, instructions for use manual and clinical trial details, as applicable, visit us at skinpen.com and micropenevo.com.

Instagram LinkedIn

©2026 REVANCE. RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by REVANCE. All other trademarks are the property of their respective owners. CORP-00147

Intended for U.S. audiences

California Compliance DeclarationPrivacy PolicyTerms of UseMap policyHealth Data Privacy Policy